Photo from Tom Powles/X
Jun 5, 2024, 12:44
Tom Powles: Perhaps the most important long-term bladder cancer data at ASCO24
Tom Powles, Director of Barts Cancer Center, shared on X/Twitter:
”Perhaps the most important long-term bladder cancer data at ASCO24. Neoadjuvant, Toripalimab and disitimab Vedotin in muscle invasive bladder cancer (n=47). pCR increased by 63%. 14% G3/4 AEs. All surgeries occurred . The 1st MMAE/IO neoadjuvant combo data looks. EV/IO MIBC trials awaited.”
Source: Tom Powles/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 7, 2024, 19:46
Nov 7, 2024, 19:43
Nov 7, 2024, 19:36
Nov 7, 2024, 19:32
Nov 7, 2024, 19:28
Nov 7, 2024, 19:24
Nov 7, 2024, 19:11
Nov 7, 2024, 18:06